Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,855,198 | 7,862,340 | 5,673,535 | 3,936,504 | 2,142,868 |
| Depreciation Amortization | 247,708 | 1,042,459 | 720,743 | 469,898 | 248,820 |
| Accounts receivable | N/A | -1,404,247 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 951,127 | N/A | N/A | N/A |
| Other Working Capital | -1,472,126 | -755,578 | -680,288 | 855,426 | 285,464 |
| Other Operating Activity | 2,665,417 | 3,474,298 | 3,998,656 | 1,537,393 | 879,617 |
| Operating Cash Flow | $4,296,197 | $11,170,400 | $9,712,646 | $6,799,221 | $3,556,769 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 69,456 | -413,614 | 558,654 | 451,737 | -278,226 |
| PPE Investments | -676,261 | -1,719,874 | -972,131 | -565,565 | -229,216 |
| Net Acquisitions | N/A | -1,001,820 | N/A | N/A | N/A |
| Purchase Of Investment | -340,220 | -23,930 | -894,333 | -702,273 | -1,056 |
| Sale Of Investment | 4,755 | N/A | -947 | N/A | 260,130 |
| Purchase Sale Intangibles | -15,563 | -369,151 | -188,744 | -57,200 | -39,208 |
| Other Investing Activity | -15,563 | -369,151 | -188,743 | -57,200 | -39,208 |
| Investing Cash Flow | $-957,833 | $-3,528,389 | $-1,497,500 | $-873,301 | $-287,576 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 1,504,536 | 1,590,160 | 1,676,896 |
| Debt Issued | N/A | 1,588,044 | N/A | 4,290 | 4,524 |
| Debt Repayment | -68,880 | -1,929,017 | -1,812,885 | -1,873,157 | -1,938,534 |
| Common Stock Repurchased | -749,176 | -3,410,578 | -2,238,809 | -1,705,561 | -675,132 |
| Dividend Paid | -2,642,362 | -3,582,905 | -3,423,496 | -2,243,670 | -2,366,052 |
| Other Financing Activity | 488,932 | 1 | 0 | 0 | 412,740 |
| Financing Cash Flow | $-2,971,486 | $-7,334,455 | $-5,970,654 | $-4,227,938 | $-2,885,558 |
| Exchange Rate Effect | -37,898 | -33,701 | 81,992 | 23,309 | -8,294 |
| Beginning Cash Position | 1,823,297 | 1,517,810 | 1,450,281 | 1,532,817 | 1,616,425 |
| End Cash Position | 2,152,278 | 1,791,665 | 3,776,764 | 3,254,108 | 1,991,766 |
| Net Cash Flow | $328,980 | $273,854 | $2,326,483 | $1,721,291 | $375,341 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,296,197 | 11,170,400 | 9,712,646 | 6,799,221 | 3,556,769 |
| Capital Expenditure | -676,261 | -1,719,874 | -972,131 | -565,565 | -229,216 |
| Free Cash Flow | 3,619,936 | 9,450,526 | 8,740,516 | 6,233,656 | 3,327,553 |